Latest Headlines

  1. Genentech And NVIDIA Enter Into Strategic AI Research Collaboration To Accelerate Drug Discovery And Development 11/21/2023

    Genentech, a member of the Roche Group today announced a multi-year strategic research collaboration with NVIDIA that couples Genentech’s artificial intelligence (AI) capabilities, extensive biological and molecular datasets, and research expertise with NVIDIA’s world-leading accelerated computing capabilities and AI to speed up drug discovery and development.

  2. Immix Biopharma Announces FDA Approval Of IND Application For CAR-T NXC-201, Enabling U.S. Patient Dosing 11/21/2023

    Immix Biopharma, Inc. (Nasdaq:IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company advancing personalized therapies for oncology and immunology, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for BCMA CAR-T NXC-201 (formerly HBI0101).

  3. HOOKIPA Pharma Announces FDA Clearance Of Its Investigational New Drug Application For HB-500 For The Treatment Of Human Immunodeficiency Virus 11/20/2023

    HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the Company has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for HB-500, a novel arenaviral therapeutic vaccine for the treatment of HIV.

  4. FDA Grants Orphan Drug Designation To NeoImmuneTech's NT-I7 For The Treatment Of Acute Radiation Syndrome 11/20/2023

    NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), a clinical-stage T cell-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for their investigational drug NT-I7 (efineptakin alfa) (rhIL-7-hyFc) for the treatment of Acute Radiation Syndrome (ARS).

  5. Sanyou's ‘STAL Platform’ Is A Significant Advancement In The Field Of Drug Discovery. 11/17/2023

    Sanyou's "STAL Innovative Biologics Drug Discovery Platform" is a significant advancement in the field of drug discovery.

  6. University Of Tsukuba And Astellas Confirm A Strategic Partnership 11/16/2023

    University of Tsukuba (President: Kyosuke Nagata) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that they have signed a letter of confirmation regarding a strategic partnership to accelerate the digitalization of the drug discovery research field, as well as the development of the life science ecosystem in Tsukuba and Kashiwa-no-ha, and to further accelerate innovative drug discovery research and development.

  7. Momentum Biotechnologies And Axxam S.p.A. Announce Collaboration To Provide Unique Drug Discovery Solutions 11/16/2023

    Axxam S.p.A. and Momentum Biotechnologies have announced a partnership to provide unique drug discovery solutions for biotechnology and pharmaceutical clients.

  8. PostEra Announces A Research Collaboration With Amgen To Discover Small Molecule Therapeutics Using Artificial Intelligence 11/16/2023

    PostEra, a biotechnology company specializing in artificial intelligence for preclinical drug discovery, today announced a multi-target collaboration with Amgen, a leading biotechnology company.

  9. Cell-Free Quest For New Antibiotics 11/16/2023

    The rising resistance of bacteria to antibiotics presents an escalating global health risk. Now, researchers at the Max Planck Institute for Terrestrial Microbiology have combined synthetic biology and artificial intelligence (AI) to develop a more efficient approach to finding and creating new antimicrobial peptides that are effective against a wide range of bacteria.

  10. Chemomab Therapeutics Receives FDA Fast Track Designation For CM-101 For The Treatment Of Primary Sclerosing Cholangitis 11/15/2023

    Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted CM-101 Fast Track designation for the treatment in adult patients of primary sclerosing cholangitis (PSC), a fibrotic liver disease that can result in liver transplant, cancer and early death.